WASHINGTON—Covington represented Humacyte, Inc. in the successful completion of its business combination with Alpha Healthcare Acquisition Corp., a special purpose acquisition company. As a result of the business combination, Humacyte has received gross proceeds of approximately $245 million, including a $175 million PIPE financing and $70 million of cash held in the former Alpha Healthcare trust account.
Humacyte commenced trading of its shares of common stock and warrants on the Nasdaq Global Select Market® under the ticker symbols "HUMA" and “HUMAW,” respectively, on August 27, 2021.
Humacyte is a clinical-stage biotechnology developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
The Covington corporate team included Kerry Burke, Brian K. Rosenzweig, Mike Riella, Jack Bodner, Sarah Griffiths, Julie Plyler, Will Mastrianna, Sebastian Marotta, Ann Peterson, Andrew Klimek, Joe DuChane, and Gustavo Akkerman, with assistance from Scott Cunningham and Matt Hegreness (FDA regulatory), Will Woolston and Megan Woodford (employee benefits), and Lee Kelley, Ansgar Simon, and Shae Qian (tax).
Back
